18-036 - RIN-PH-202 An Open -Label Extension Study of Inhaled Treprostinil in Subjects with pulmonary Hypertension due to Parenchymal Lung DiseaseStatus: open
18-036 - RIN-PH-202 An Open -Label Extension Study of Inhaled Treprostinil in Subjects with pulmonary Hypertension due to Parenchymal Lung Disease
Treatment for Pulmonary Arterial Hypertension
This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 266 patients who completed all required assessments in the RIN-PH-201 study at approximately 100 clinical trial centers. The study will continue Your participation in this study is voluntary and will last until you discontinue from the study or the study ends. The study will continue until each subject reaches the Week 108 visit or until inhaled treprostinil become commercially available for patients with PH associated with ILD including CPFE (whichever is sooner). IRB 18-036
Interested in Clinical Trial?
Providers Associated With This Trial
- Karen A. Fagan, M.D.PulmonologistDirector of Division Pulmonary & Critical Care; Director of Pulmonary Hypertension Center; Associate Professor of Internal Medicine